Remus Pharmaceuticals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/l6kz8czb8oej9bcdyp6v8q7n.pdf

Key Takeaways


Standalone vs Consolidated: Two Different Stories

Arpit Shah: "This year, we got some opportunity of around USD 12 million of one of a couple of orders, which were very low margins, like gross margin, we did around 2% give or take. And that was in advance, and we had the payments in advance, there was no cash flow with. So, we took that order in an opportunity that this will also create a new opportunity for H2 to get newer products and newer orders."

Espee Global: The Margin Overhang

Arpit Shah: "If you are looking at a long term, we are eyeing to at least do 5% to 7% on it, which is our goal and with biosimilars and expensive products coming in our portfolio at Espee, we think that is really much achievable because the access of such products, there is no competition."

B2C Build-Out: Investment Mode

Arpit Shah: "B2C is not an overnight exercise that we have at Pharma... building a brand takes time and we are already on it from last 1 year, 1.5 year. And we are getting there in terms of watching our numbers to make sure that B2C grows faster. But at the same point of time, we do not also lose track on our B2B business, which also gives us a good top line as well as bottom line."

Regulatory Portfolio & Geographic Expansion


Product Pipeline: GLP-1, Patches, Biosimilars

Arpit Shah: "We are currently in discussion to in license several additional biosimilar products, which, if concluded, would further strengthen our presence in specialized and differentiated therapeutic categories that we offer in this market."

Capital Allocation & Corporate Actions

Arpit Shah: "Main board is inevitable and we are excited to move to that."

Guidance & Commitments

CommitmentSpecificsTimeline
Espee margin improvementH2 will have better products fetching higher gross margins (not 2%); absolute EBITDA/PAT from Espee expected better than H1H2 FY27
Espee long-term margin targetEyeing 5% to 7% margins, achievable via biosimilars and biological products with limited competitionLong-term (no date)
Peru commercialization60 products filed; approvals expected in less than 4-6 months; commercialization probable in H2H2 FY27
Semaglutide commercializationCommercialization planned in near term, probably H2 FY27, pending patent expiry in certain marketsH2 FY27
Main board migrationPending items expected to close post-Diwali, before end of this monthNovember 2026
Subsidiary break-even1.5 to 3 years per country, since products are pre-registered and commercial revenue begins alongside OPEX spend1.5-3 years from incorporation
Standalone H2 growthH2 always better than H1; current order booking supports same or more growth than H1H2 FY27
B2C contribution trajectoryGrowth trajectory in line with commitments; building a brand takes time; no demarcation of doing more B2C and less B2BOngoing (no date)

Key Metrics

MetricH1 FY27
Consolidated revenue from operations₹614.12 cr, +53% YoY
Standalone revenue from operations₹62 cr, +32% YoY
Consolidated operational EBITDA₹29.93 cr, +11% YoY
Consolidated EBITDA margin5%
Standalone operational EBITDA₹22 cr, +47% YoY
Standalone EBITDA margin35%, expanded 330 bps YoY
Consolidated net profit₹24.66 cr, +14% YoY
Consolidated PAT margin4%
Standalone net profit₹19 cr, +57% YoY
Standalone PAT margin30%, improved 470 bps YoY
Consolidated net cash flow from operating activity₹8 cr
Consolidated cash and cash equivalents₹10 cr as of September 30, 2026
Interim dividend₹1 per equity share (face value ₹10), record date November 7, 2026
Global regulatory portfolio2,443 registrations and applications, comprising 955 registered and 1,448 under registration
Latin America and Caribbean regulatory portfolio1,805 registrations and applications, comprising 869 registered and 936 under registration
ASEAN regulatory portfolio406 registrations and applications, comprising 71 registered and 335 under registration
B2C revenue contribution~14% of H1 revenue (per an analyst's question, not confirmed by management)
B2C gross margin70%–80%
B2B gross margin~40%
Espee Global revenue contribution~₹550 cr in H1
Espee low-margin orders taken~USD 12 mn at ~2% gross margin
Long-term Espee margin target5%–7%
Rotigotine patch margin~75%–80% (management's margin expectation)
Bolivia tenders secured24 pharmaceutical products
Peru product filings in process60 products, approvals expected in less than 4–6 months
Venezuela additional regulatory filingsmore than 100 products
Guatemala registrations ready60-odd
Dominican Republic products approved18 products approved, 55 filed
Subsidiary break-even timeline1,000–1,200 days (~3–3.5 years) ballpark; Bolivia achieved in 1.5 years
Remus stake in Senores>7%, valued at ~₹350–400 cr
Total investments~₹490 cr, up from ₹275 cr